Skip to main content
. Author manuscript; available in PMC: 2012 Jan 1.
Published in final edited form as: Curr Drug Metab. 2011 Jan;12(1):51–56. doi: 10.2174/138920011794520008

Table 2.

Interactions or Potential Interactions between Components of cART Used in Sub Saharan Africa and Commonly Used Antimalarial Drugs*

Chloroquine Quinine Amodiquine Mefloquine Artemether LUM S-P Cotrim*
AZT
3TC
d4T
ABC
ddI
FTC
TDF
NVP NA NA + NA + + NA NA
EFV NA NA + NA + + NA NA
LPV + NA NA NA NA + NA NA
ATV NA NA NA NA NA + NA NA
SQV NA NA NA NA NA + NA NA
IDV NA NA NA NA NA + NA NA
*

Cotrimoxazole is not recommended for treatment or prophylaxis of malaria in the general population, which is included because it has been recommended for such purpose in HIV + individuals

Abbreviations: Cotrim, cotrimoxazole (sulphamethoxazole-trimethoprim); S-P, sulphadoxine-pyrimethamine; LUM, lumefantrine; AZT, zidovudine; 3TC, lamivudine; d4T, stavudine; ABC, abacavir; ddI, didanosine; FTC, emtricitabine; TDF, tenofovir; NVP, nevirapine; EFV, efavirenz; LPV, lopinavir; ATV, atazanavir; SQV, saquinavir; IDV, indinavir

− No demonstrable interaction or clinically significant interaction is unlikely

+ Documented interactions or potential for interaction is high

NA No appreciable clinical data available or data completely lacking